Equities analysts forecast that Paragon 28 will post -0.64 earnings per share for the current fiscal year. Paragon 28, Inc develops, distributes, and sells foot and ankle surgical systems in the ...

Analysts expect that Paragon 28, Inc. will post -0.64 EPS for the current year. Paragon 28, Inc develops, distributes, and sells foot and ankle surgical systems in the United States and ...

Investing.com -- Zimmer Biomet announced that it plans to acquire Paragon 28, a medical device company, for approximately $1.1 billion. This acquisition is part of Zimmer's strategy to expand its ...

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Paragon 28's stock has seen a significant recovery from its low point of $4.89 in the third quarter of 2024, with InvestingPro data showing an impressive six-month return of 38.4%.

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American College of Foot ...

ENGLEWOOD, Colo., March 07, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. for $13.00 per share in ...

ENGLEWOOD, Colo., March 24, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to ...

ENGLEWOOD, Colo., March 24, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce ...